Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 23.27
+0.02 (0.09%)
Oct 28, 2025, 3:00 PM CST
Chengdu Olymvax Biopharmaceuticals Company Description
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use.
It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine.
The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and staphylococcus aureus, which is in Phase 3 clinical trial.
In addition, it engages in technology promotion and application services business; biotechnology, R&D, and consulting.
The company was founded in 2009 and is based in Chengdu, China.
Chengdu Olymvax Biopharmaceuticals Inc.
| Country | China |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 470 |
| CEO | Shaowen Fan |
Contact Details
Address: No. 99 Tianxin Road Chengdu, 611731 China | |
| Phone | 86 28 6936 1111 |
| Website | olymvax.com |
Stock Details
| Ticker Symbol | 688319 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000051H8 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaowen Fan | Chairman of the Board and GM |
| Yong Tan | Chief Financial Officer and Deputy GM |
| Aimin Chen | Director and Deputy GM |
| Wei Wu | Secretary of the Board and Deputy GM |
| Xingyao Qin | Accounting supervisor |